Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth Inhibitors After Endoscopic Treatment for Variceal Bleeding
NCT06011980Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2023
- Primary completion
- May 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of somatostatin in Esophageal variceal hemorrhage (EVH) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: rebleeding rate after the endoscopic treatment at 1 month, rebleeding rate after the endoscopic treatment at 3 months and 1 more. Started Aug 2023; status: recruiting.
02
Drugs
somatostatin
03
Conditions
Esophageal variceal hemorrhage (EVH)
Beyond the preview
Go deeper on NCT06011980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06011980.